| 1 |
中华医学会糖尿病学分会. 中国糖尿病防治指南(2024版)[J/OL]. 中华糖尿病杂志, 2025, 17(1): 16-139.
|
| 2 |
CHRIST-CRAIN M, BICHET D G, FENSKE W K, et al. Diabetes insipidus[J/OL]. Nature reviews. Disease primers, 2019, 5: 55.
|
| 3 |
LEIGHTON E, SAINSBURY C A, JONES G C. A practical review of C-peptide testing in diabetes[J/OL]. Diabetes therapy: Research, treatment and education of diabetes and related disorders, 2017, 8(3): 475-487.
|
| 4 |
中华医学会糖尿病学分会胰岛β细胞学组, 江苏省医学会内分泌学分会. 2型糖尿病胰岛β细胞功能评估与保护临床专家共识[J]. 中华糖尿病杂志, 2022, 14(6): 533-543.
|
| 5 |
CHEN J, HUANG Y, LIU C, et al. The role of C-peptide in diabetes and its complications: An updated review[J]. Frontiers in endocrinology, 2023, 14: 1256093.
|
| 6 |
OYER P E, CHO S, PETERSON J D, et al. Studies on human proinsulin. Isolation and amino acid sequence of the human pancreatic C-peptide[J]. The journal of biological chemistry, 1971, 246(5): 1375-1386.
|
| 7 |
HENRIKSEN J H, TRONIER B, BÜLOW J B. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man[J]. Metabolism: Clinical and experimental, 1987, 36(5): 463-468.
|
| 8 |
ZAVARONI I, DEFERRARI G, LUGARI R, et al. Renal metabolism of C-peptide in man[J]. The journal of clinical endocrinology and metabolism, 1987, 65(3): 494-498.
|
| 9 |
白轩畅, 徐恺铎, 孙运苗, 等. 我国C肽检测的室间质量评价结果分析[J]. 中华糖尿病杂志, 2026, 18(1): 42-50.
|
| 10 |
ZHOU W, DENG Y, ZHAO H, et al. Current status of serum insulin and C-peptide measurement in clinical laboratories: experience from 94 laboratories in China[J]. Annals of laboratory medicine, 2022, 42(4): 428-437.
|
| 11 |
LITTLE R R, ROHLFING C L, TENNILL A L, et al. Standardization of C-peptide measurements[J]. Clinical chemistry, 2008, 54(6): 1023-1026.
|
| 12 |
马洁, 郭立新. C肽检测标准化势在必行[J]. 中华糖尿病杂志, 2025, 17(12): 1549-1553.
|
| 13 |
DENG Y, ZHANG C, WANG J, et al. An accurate isotope dilution liquid chromatography-tandem mass spectrometry method for serum C-peptide and its use in harmonization in China[J]. Annals of laboratory medicine, 2023, 43(4): 345-354.
|
| 14 |
DENG Y, ZHANG C, LI B, et al. Exploration of suitable external quality assessment materials for serum C-peptide measurement[J]. Clinical chemistry and laboratory medicine, 2023, 61(9): 1597-1604.
|
| 15 |
周伟燕, 刘庆香, 刘珍妮, 等. 计量溯源性和临床检验参考系统[J]. 临床检验杂志, 2020, 38(10): 721-728.
|
| 16 |
INTERNATIONAL ORGANIZATION FOR STANDARDIZATION. In vitro diagnostic medical devices—Requirements for establishing metrological traceability of values assigned to calibrators, trueness control materials and human samples: ISO 17511:2020[S]. Geneva: International Organization for Standardization, 2020.
|
| 17 |
WHITE G H. Metrological traceability in clinical biochemistry[J]. Annals of clinical biochemistry, 2011, 48(Pt 5): 393-409.
|
| 18 |
GREENBERG N. Update on current concepts and meanings in laboratory medicine-Standardization, traceability and harmonization[J]. Clinica chimica acta; international journal of clinical chemistry, 2014, 432: 49-54.
|
| 19 |
INTERNATIONAL ORGANIZATION FOR STANDARDIZATION. In vitro diagnostic medical devices—Measurement of quantities in samples of biological origin—Requirements for content and presentation of reference measurement procedures: ISO 15193:2009[S]. Geneva: International Organization for Standardization, 2009.
|
| 20 |
INTERNATIONAL ORGANIZATION FOR STANDARDIZATION. In vitro diagnostic medical devices—Measurement of quantities in samples of biological origin—Requirements for certified reference materials and the content of supporting documentation: ISO 15194:2009[S]. Geneva: International Organization for Standardization, 2009.
|
| 21 |
CLINICAL AND LABORATORY STANDARDS INSTITUTE. Evaluation of commutability of processed samples: CLSI EP14[S]. Wayne, PA: Clinical and Laboratory Standards Institute, 2022.
|
| 22 |
MILLER W G, MYERS G L. Commutability still matters[J]. Clinical chemistry, 2013, 59(9): 1291-1293.
|
| 23 |
CLINICAL AND LABORATORY STANDARDS INSTITUTE. User verification of precision and estimation of bias; approved guideline-third edition: CLSI EP15-A3[S]. Wayne, PA: Clinical and Laboratory Standards Institute, 2014.
|
| 24 |
JOINT COMMITTEE FOR GUIDES IN METROLOGY. Guide to the expression of uncertainty in measurement-Part 6: Developing and using measurement models: JCGM GUM-6:2020[Z/OL]. [2026-01-16].
|
| 25 |
CLINICAL AND LABORATORY STANDARDS INSTITUTE. Evaluation of commutability of processed samples guide: CLSI EP14 Guide[S]. Wayne, PA: Clinical and Laboratory Standards Institute, 2025.
|
| 26 |
MORADIAN A, GOONATILLEKE E, LIN T T, et al. Interlaboratory comparison of antibody-free LC-MS/MS measurements of C-peptide and insulin[J]. Clinical chemistry, 2024, 70(6): 855-864.
|
| 27 |
STOYANOV A V, CONNOLLY S, ROHLFING C L, et al. Human C-peptide quantitation by LC-MS isotope-dilution assay in serum or urine samples[J]. Journal of chromatography & separation techniques, 2013, 4(3): 172.
|
| 28 |
ROGATSKY E, BALENT B, GOSWAMI G, et al. Sensitive quantitative analysis of C-peptide in human plasma by 2-dimensional liquid chromatography-mass spectrometry isotope-dilution assay[J]. Clinical chemistry, 2006, 52(5): 872-879.
|
| 29 |
GOROVITS B, MCNALLY J, FIOROTTI C, et al. Protein-based matrix interferences in ligand-binding assays[J]. Bioanalysis, 2014, 6(8): 1131-1140.
|
| 30 |
WOOD W G. “Matrix effects” in immunoassays[J]. Scandinavian journal of clinical and laboratory investigation. supplementum, 1991, 205: 105-112.
|